Pharmaceutical Information and Graded-Plan Officers under the German AMG

The pharmaceutical industry in Germany operates under one of the world's most stringent regulatory environments. At the heart of this system is the German Medicines Act (Arzneimittelgesetz - AMG), a federal statute designed to guarantee the safety, quality, and efficacy of medicinal products. Under the AMG, pharmaceutical companies cannot simply market products without establishing a rigorous, legally compliant organizational structure. The law mandates the appointment of specialized corporate officers who assume personal responsibility for distinct compliance domains. This regulatory design ensures that scientific accuracy and drug safety are prioritized over commercial interests, protecting both patients and healthcare professionals.

A central concept in German pharmaceutical regulation is the pharmaceutical entrepreneur (pharmazeutischer Unternehmer, often abbreviated as pU). According to Section 4 Paragraph 18 of the AMG, the pharmaceutical entrepreneur is the entity that places finished medicinal products (Fertigarzneimittel) on the market under its own name. This classification applies to local manufacturers, international pharmaceutical groups operating in Germany, and distributors who rebrand or repackage products. The pharmaceutical entrepreneur bears ultimate accountability for compliance. Because of this high exposure, managing directors and HSE leads must ensure that all legally required officer roles are correctly appointed and integrated into their corporate governance.

To prevent conflicts of interest and ensure highly specialized supervision, the AMG divides regulatory responsibilities into two distinct officer roles. The first is the Pharmaceutical Information Officer (Informationsbeauftragter) appointed under Section 74a of the AMG, who is responsible for the scientific and medical accuracy of product labeling, package leaflets, and promotional materials[1]. The second is the Graded-Plan Officer (Stufenplanbeauftragter) appointed under Section 63a of the AMG, who acts as the primary contact for pharmacovigilance, collecting and evaluating reports of adverse drug reactions. While these roles address different aspects of compliance, they are closely linked; in fact, the AMG explicitly allows a single qualified individual to hold both positions simultaneously if they possess the necessary qualifications[1].

Operating within Germany's strict legal boundaries, companies must treat these appointments as critical elements of their broader compliance framework. Managing these roles demands precise execution, much like coordinating other specialized compliance officers who secure business operations. To prevent administrative fines or operational shutdowns, managing directors and functional leads must implement structured processes for the appointment, training, and continuous documentation of these critical pharmaceutical roles.

In Germany, pharmaceutical manufacturers who place finished medicinal products (Fertigarzneimittel) on the market are legally obligated to appoint a dedicated corporate officer to oversee scientific product information. This role, known as the Pharmaceutical Information Officer (Informationsbeauftragter), is established under Section 74a of the German Medicines Act (Arzneimittelgesetz - AMG)[2]. For managing directors, compliance leads, and international groups with German operations, establishing this function correctly is critical to avoiding regulatory sanctions and ensuring complete compliance across all drug-marketing activities.

• Legal Mandate: Section 74a of the German Medicines Act (Arzneimittelgesetz - AMG) makes the appointment mandatory for pharmaceutical companies marketing finished drugs.
• Primary Scope: Oversight of scientific product information, including labeling, package inserts, and summary of product characteristics (SmPC).
• Key Prohibition: Ensuring that no misleading advertising or inaccurate claims are distributed, which would violate Section 8(1) No. 2 AMG.
• Reporting Requirement: The appointment and any subsequent changes must be formally notified to the competent regional authority in Germany.

The daily responsibilities of the Pharmaceutical Information Officer are highly critical to corporate compliance compliance officer. Under Section 74a AMG, the officer must ensure that all labeling, package leaflets, expert product information (Fachinformation), and advertising materials correspond exactly to the details approved in the drug's official marketing authorization[3]. The officer acts as an internal clearinghouse, reviewing and signing off on all promotional campaigns and medical publications before they reach healthcare professionals or patients.

A central objective of this function is to prevent violations of Section 8(1) No. 2 AMG, which strictly prohibits the distribution of medicines with misleading designations, therapeutic indications, or visual presentations. Additionally, the Pharmaceutical Information Officer coordinates directly with federal regulatory authorities, manages the creation of mandatory medical texts, and oversees the training of sales representatives to guarantee that all scientific communication in the field remains compliant and risk-free.

The German Medicines Act does not allow just any corporate representative to take on this regulatory role. To be appointed as an Informationsbeauftragter, an individual must possess the necessary scientific expertise (Sachkenntnis) and personal reliability required to perform their duties. According to German regulatory standards, this scientific expertise is formally aligned with the qualification pathways set out under Section 75 of the AMG.

Beyond academic credentials, the appointed officer must demonstrate personal reliability (Zuverlässigkeit) to ensure independent and ethical decision-making in the face of commercial pressures. The company is legally responsible for verifying and documenting these credentials. Utilizing a specialized tool like the CIVAC platform can streamline the formal verification of qualifications and maintain audit-proof documentation for regular regulatory inspections.

Under German pharmaceutical law, any pharmaceutical entrepreneur placing finished medicinal products on the market is legally required to appoint a Graded-Plan Officer, known in Germany as the Stufenplanbeauftragter. This appointment obligation is strictly anchored in Section 63a of the German Medicines Act (Arzneimittelgesetz - AMG). The primary mandate of this officer is to set up and manage a robust pharmacovigilance system, collect and evaluate notifications of medicinal product risks, and coordinate all necessary defensive measures. This role is a critical component of the corporate compliance framework, comparable in regulatory importance to other specialized safety roles managed through the CIVAC compliance platform.

The operational duties of the Graded-Plan Officer focus heavily on drug safety and risk mitigation. The officer is personally responsible for meeting all statutory notification obligations regarding drug risks to the competent federal authorities, namely the Federal Institute for Drugs and Medical Devices (BfArM) or the Paul-Ehrlich-Institut (PEI)[4]. Furthermore, the officer must ensure that any supplementary information required to evaluate the risk-benefit profile of a medicinal product, including personal scientific assessments, is submitted immediately and in full upon official request. Beyond risk collection, they manage complaints and coordinate product recalls in accordance with Section 19 of the Ordinance on the Manufacture of Medicinal Products and Active Substances (AMWHV).

To assume this high-responsibility role, the appointee must reside within a member state of the European Union, possess verified reliability, and demonstrate extensive expert knowledge. Under Section 63a paragraph 3 AMG, this expertise is validated by a university degree in medicine, pharmacy, veterinary medicine, biology, or chemistry, combined with at least two years of practical experience in pharmacovigilance[4]. The German Graded-Plan Officer operates in close alignment with the European Qualified Person for Pharmacovigilance (QPPV). While centrally authorized EU products only require a QPPV, national, decentralized (DCP), or mutual recognition (MRP) marketing authorizations in Germany mandate a locally registered Graded-Plan Officer. If the EU QPPV does not speak German, a local representative must be appointed to assist with German-language pharmacovigilance and authority communication.

• Legal Mandate: Strictly required under Section 63a of the German Medicines Act (AMG) for finished medicinal products.
• Key Responsibility: Systematically records, evaluates, and reports drug risks, and coordinates safety measures such as product recalls.
• Qualifications: University degree in life sciences (medicine, pharmacy, biology, or chemistry) plus at least two years of pharmacovigilance experience.
• Registration: Mandatory notification via the PharmNet.Bund portal to BfArM or PEI before the officer officially starts their service.
• European Alignment: Works in tandem with the EU QPPV, acting as the local German-speaking pharmacovigilance anchor when required.

The appointment of the Graded-Plan Officer must follow a strict administrative workflow. Pharmaceutical entrepreneurs must register the officer and any deputies through the online PharmNet.Bund portal prior to the start of their service. Unforeseen changes must be reported within one week. Failure to appoint, register, or maintain a qualified Graded-Plan Officer constitutes a severe compliance violation. Under Section 97 of the AMG, non-compliance is classified as an administrative offense, exposing managing directors and the company to substantial administrative fines. Furthermore, because the officer carries personal legal responsibility for notifying authorities of safety risks, accurate, audit-proof logging of all risk assessments is critical to protect both the individual officer and the corporate entity from personal liability.

Operating a pharmaceutical company in Germany requires strict adherence to the German Medicines Act (Arzneimittelgesetz - AMG). To ensure compliance, manufacturers must designate qualified individuals for highly specialized regulatory roles. While the Pharmaceutical Information Officer (Informationsbeauftragter) and the Graded-Plan Officer (Stufenplanbeauftragter) cooperate closely, they serve separate functions. Understanding their legal differences and the operational synergies of a dual appointment is key for compliance leads and managing directors.

The core functional differences lie between scientific product information compliance and active risk management. The Pharmaceutical Information Officer focuses on truth in marketing, scientific accuracy, and the conformity of labels with the official marketing authorization. In contrast, the Graded-Plan Officer operates the pharmacovigilance system. This role involves collecting, evaluating, and reporting adverse events to federal authorities like the Federal Institute for Drugs and Medical Devices (BfArM) or the Paul-Ehrlich-Institut (PEI).

German law provides a highly practical path for companies aiming to streamline corporate officer appointments. Under Section 74a Paragraph 2 of the German Medicines Act, the Pharmaceutical Information Officer is explicitly permitted to simultaneously serve as the Graded-Plan Officer[5]. This dual appointment is particularly common in small and medium-sized enterprises (SMEs) to control administrative overhead and avoid redundant staffing.

Combining these positions creates immediate operational synergies. A dual-role officer can seamlessly bridge the gap between safety findings and information updates. For example, if the Graded-Plan Officer identifies a critical new side effect, the same individual, acting as the Information Officer, can immediately initiate updates to the summary of product characteristics (Fachinformation) and patient package leaflets.

However, dual-role officers face intense workloads and complex legal exposure. Managing both regulatory mandates without digital support can lead to documentation gaps or missed deadlines. This is where centralized tools like the CIVAC Workspace prove invaluable to support internal compliance officers. By using the CIVACCIVAC Compliance-Plattform, managing directors and compliance leads can track tasks, manage required training, and create an audit-proof trail for all corporate officer activities. Utilizing the services of offers structured management software to help companies appoint or supervise these mandatory roles safely.

Operating in the pharmaceutical sector in Germany requires strict adherence to corporate and regulatory compliance standards. Under the German Medicines Act (Arzneimittelgesetz, or AMG), the failure to appoint mandatory compliance roles is treated as a serious regulatory infraction rather than a mere administrative oversight. Both the Pharmaceutical Information Officer (Informationsbeauftragter) and the Graded-Plan Officer (Stufenplanbeauftragter) are legally required positions that act as structural shields against product safety and communication risks. For managing directors, compliance leads, and international groups with German operations, understanding the specific liability regimes under Section 97 AMG is crucial to avoiding severe personal and corporate consequences.

The statutory framework provides clear financial penalties to enforce these appointments. Under Section 97 Paragraph 3 of the AMG, the regulatory authorities can impose administrative fines of up to 25,000 Euro for non-compliance with the appointment obligations or for failing to properly notify the authorities of the officer's identity and qualifications[6]. This fine applies directly if a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) puts medicinal products on the market without an active, qualified Graded-Plan Officer under Section 63a, or without a Pharmaceutical Information Officer under Section 74a. This penalty can be issued for each day or instance of non-compliance, meaning that ongoing structural deficits can quickly lead to compounding financial and operational penalties.

The distinction between corporate liability and personal liability is a critical aspect of German compliance law. While the appointed officers carry immediate operational responsibility for their specialized duties, corporate management retains an overarching duty of supervision. Under Section 130 of the German Act on Regulatory Offenses (Ordnungswidrigkeitengesetz, or OWiG), directors can be held personally liable for organizational culpability (Organisationsverschulden) if a lack of proper supervision or selection of the officer enables a legal violation. For complex compliance officers and highly regulated roles, this means that merely appointing a professional is not sufficient; management must also prove that they have actively supervised the officers and provided them with the necessary resources to execute their legal mandates.

To effectively mitigate both individual and corporate liability, pharmaceutical companies must establish structured, unalterable documentation of all compliance processes. In the event of a regulatory inspection or a product safety crisis, the burden of proof rests on the company and its management to demonstrate that they fulfilled their organizational duties. A lack of transparent records can be interpreted as a failure of oversight, triggering regulatory interventions, product recalls, and administrative fines. Implementing standardized workflows for task tracking, reporting, and continuous training is the only reliable way to protect both the managing directors and the appointed officers from liability exposure.

To ensure that the organization can confidently present this evidence during official regulatory audits, companies are increasingly shifting away from manual spreadsheets and adopting centralized systems. Utilizing a digital compliance platform like the CIVAC Workspace makes audit preparation far more efficient, ensuring that all appointment certificates, training protocols, and task logs are instantly accessible. This level of preparation serves as an audit-proof paper trail, verifying that management has exercised due diligence in selecting, training, and supervising their mandatory officers.

• Maintain clear, signed appointment certificates detailing the exact legal basis and scope of duties for both officers.
• Log all communication with German regulatory bodies, such as the Federal Institute for Drugs and Medical Devices (BfArM), including immediate notifications of any officer changes.
• Document regular training sessions and qualification verifications to ensure the officers remain current on evolving pharmacovigilance and information regulations.
• Implement an unalterable, timestamped task management system to record all decisions made by the Graded-Plan Officer regarding potential drug risks.

Fulfilling the rigorous regulatory demands of the German Medicines Act (Arzneimittelgesetz - AMG) requires precise oversight and continuous documentation. For managing directors and corporate compliance leads, maintaining a clear audit trail for specialized roles like the graded-plan officer (Stufenplanbeauftragter) and pharmaceutical information officer (Informationsbeauftragter) is a critical compliance mandate. Regulatory authorities demand that qualifications, mandatory training, and specific operational actions be recorded in an audit-proof format[7]. To mitigate liability risks and streamline these complex workflows, CIVAC provides tailored solutions that help organizations manage their legal obligations efficiently.

The CIVAC Workspace serves as a centralized compliance platform designed to orchestrate all internal officer tasks, training schedules, and mandatory documentation. Instead of relying on fragmented spreadsheets or decentralized folders, compliance managers can use the digital platform to assign tasks, schedule scientific reviews, and record pharmacovigilance reports in real time. This structured approach simplifies audit preparation by establishing an immutable history of compliance actions, ensuring that the company can readily demonstrate regulatory compliance to supervisory bodies during official inspections.

• Centralized task tracking to manage recurring scientific product information reviews and pharmacovigilance deadlines.
• Audit-proof storage for professional certifications, CVs, and continuous education certificates of the appointed officers.
• Integrated training modules to ensure that internal staff remain up to date on evolving European and national regulatory guidelines.
• Automated warning systems that alert management before crucial compliance deadlines or training renewal dates expire.

For pharmaceutical companies that prefer to delegate operational tasks and minimize internal liability, outsourcing these demanding roles is a highly effective strategy[8]. Through the specialized service CIVAC Externe Beauftragte, organizations can securely appoint qualified external officers to fulfill their legal mandates. This model ensures that certified professionals handle all critical tasks, including drug risk assessments and scientific marketing compliance, while providing managing directors with reliable protection against personal administrative fine exposure.

A Pharmaceutical Information Officer (Informationsbeauftragter) is a legally mandated corporate role under Section 74a of the German Medicines Act (AMG). This officer is responsible for ensuring that all scientific product information, packaging leaflets, labeling, and advertising material comply with the approved marketing authorization and are scientifically accurate.

A Graded-Plan Officer (Stufenplanbeauftragter) is a pharmacovigilance role mandated under Section 63a of the German Medicines Act (AMG). This officer is responsible for establishing and maintaining a system to collect, evaluate, and report medicinal risks, side effects, and coordinate required risk-mitigation measures with federal authorities.

Yes, Section 74a Paragraph 2 of the AMG explicitly permits the Pharmaceutical Information Officer to also act as the Graded-Plan Officer, provided they possess the required qualification and expertise for both functions and have the operational capacity to fulfill all duties.

The Pharmaceutical Information Officer must possess the required expertise (Sachkenntnis) under Section 75 AMG, typically proven by a university degree in pharmacy, medicine, biology, or chemistry, combined with relevant professional experience. The Graded-Plan Officer must also have suitable scientific qualification and professional pharmacovigilance expertise.

Under Section 97 of the AMG, failing to appoint a mandatory Pharmaceutical Information Officer or a Graded-Plan Officer is classified as an administrative offense. This violation can lead to regulatory fines of up to 25000 Euro against the company and its management.

While the EU mandates a Qualified Person for Pharmacovigilance (QPPV) at the European level, Germany maintains the Graded-Plan Officer as a distinct national requirement. The Graded-Plan Officer coordinates closely with the EU QPPV but remains personally responsible for local German regulatory reporting and risk management.